Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers

  • Kyunghwa Han (Department of Radiology, Research Institute of Radiological Science, and Center for Clinical Imaging Data Science, Yonsei University College of Medicine) ;
  • Inkyung Jung (Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine)
  • Received : 2022.01.26
  • Accepted : 2022.03.20
  • Published : 2022.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

Acknowledgement

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1I1A1A01059893).

References

  1. Park SY, Park JE, Kim H, Park SH. Review of statistical methods for evaluating the performance of survival or other time-to-event prediction models (from conventional to deep learning approaches). Korean J Radiol 2021;22:1697-1707 
  2. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 2014;32:2380-2385 
  3. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 2011;30:2409-2421 
  4. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;13:152 
  5. Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, et al. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. JAMA Oncol 2017;3:1692-1696 
  6. Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol 2016;34:1813-1819 
  7. Harhay MO, Porcher R, Cantu E, Crowther MJ, Christie JD, Thabut G, et al. An alternative approach for the analysis of time-to-event and survival outcomes in pulmonary medicine. Am J Respir Crit Care Med 2018;198:684-687 
  8. Perego C, Sbolli M, Specchia C, Fiuzat M, McCaw ZR, Metra M, et al. Utility of restricted mean survival time analysis for heart failure clinical trial evaluation and interpretation. JACC Heart Fail 2020;8:973-983 
  9. Kim DH, Uno H, Wei LJ. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol 2017;2:1179-1180 
  10. Irwin JO. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hyg (Lond) 1949;47:188 
  11. Liang F, Zhang S, Wang Q, Li W. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. Ann Oncol 2018;29:1320-1324 
  12. Cronin A, Tian L, Uno H. Strmst2 and Strmst2pw: new commands to compare survival curves using the restricted mean survival time. Stata J 2016;16:702-716 
  13. Uno H, Tian L, Horiguchi M, Cronin A, Battioui C, Bell J. survRM2: comparing restricted mean survival time. R package version 1.0-3. CRAN.R-project.org Web site. https://CRAN.R-project.org/package=survRM2. Accessed March 2, 2022 
  14. MedCalc. Kaplan Meier survival analysis. medcalc.org Web site. https://www.medcalc.org/manual/kaplan-meier.php. Accessed March 2, 2022 
  15. Guo C, Liang Y. Analyzing restricted mean survival time using SAS/STAT®. sas.com Web site. https://www.sas.com/content/dam/SAS/support/en/sas-global-forum-proceedings/2019/3013-2019.pdf. Accessed March 2, 2022 
  16. Park SH, Han K, Park SY. Mistakes to avoid for accurate and transparent reporting of survival analysis in imaging research. Korean J Radiol 2021;22:1587-1593 
  17. Dehbi HM, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ 2017;357:j2250 
  18. Zhuang BW, Li W, Wang W, Li B, Lu MD, Kuang M, et al. Treatment effect of radiofrequency ablation versus liver transplantation and surgical resection for hepatocellular carcinoma within Milan criteria: a population-based study. Eur Radiol 2021;31:5379-5389 
  19. Chen MY, Rochitte CE, Arbab-Zadeh A, Dewey M, George RT, Miller JM, et al. Prognostic value of combined CT angiography and myocardial perfusion imaging versus invasive coronary angiography and nuclear stress perfusion imaging in the prediction of major adverse cardiovascular events: the CORE320 multicenter study. Radiology 2017;284:55-65 
  20. Liao JJZ, Liu GF, Wu WC. Dynamic RMST curves for survival analysis in clinical trials. BMC Med Res Methodol 2020;20:218 
  21. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, et al. Alternatives to Hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med 2015;163:127-134 
  22. Mozumder SI, Rutherford MJ, Lambert PC. Estimating restricted mean survival time and expected life-years lost in the presence of competing risks within flexible parametric survival models. BMC Med Res Methodol 2021;21:52 
  23. Calkins KL, Canan CE, Moore RD, Lesko CR, Lau B. An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use. BMC Med Res Methodol 2018;18:27 
  24. Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal 2004;10:335-350 
  25. Tian L, Zhao L, Wei LJ. Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. Biostatistics 2014;15:222-233